Multicenter, placebo-controlled trial of lorcaserin for weight management

New England Journal of Medicine

Volumn 363, Issue 3, 2010, Pages 245-256

  Smith, Steven R ^a   Weissman, Neil J ^b   Anderson, Christen M ^c   Sanchez, Matilde ^c   Chuang, Emil ^c   Stubbe, Scott ^c   Bays, Harold ^d   Shanahan, William R ^c  

^a FLORIDA HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ARENA PHARMACEUTICALS   (United States)

^d LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LORCASERIN; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; BRONCHITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIET; DISEASE MARKER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG SAFETY; EXERCISE; EYE DISEASE; FATIGUE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GENETIC DISORDER; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFESTATION; INFLUENZA; INSOMNIA; INSULIN BLOOD LEVEL; LARYNX PAIN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SINUS CONGESTION; SINUSITIS; SORE THROAT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VALVULAR HEART DISEASE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77954635020     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0909809     Document Type: Article

References (31)

1. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323-8.
2. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297:609-11.
3. Xu Y, Jones JE, Kohno D, et al. 5-HT-2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008;60:582-9.
4. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002;95:73-88.
5. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
6. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
7. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002; 144:1065-73. (Pubitemid 36026921)
8. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32.
9. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
10. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
11. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
12. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-87.
13. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 2008;51:305-13.
14. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2008;17:494-503.
15. World Health Organization. Energy and protein requirements. In: Report of a joint FAO/WHO/ONU expert consultation. 10th ed. WHO technical report series 724. Geneva: World Health Organization, 1985: 71-80.
16. Gottdiener JS, Panza JA, St John Sutton M, Bannon P, Kushner H, Weissman NJ. Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation. Am Heart J 2002;144:115-21. (Pubitemid 34734764)
17. Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. Eur J Clin Nutr 2002; 56:264-70. (Pubitemid 34228826)
18. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
19. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000;8:270-8.
20. Karason K, Lindroos AK, Stenlöf K, Sjöström L. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med 2000;160:1797-802. (Pubitemid 30418817)
21. National Cholesterol Education Program of the National Institutes of Health (NIH), National Heart Lung and Blood Institute. Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). (Accessed April 1, 2010, at http://hp2010.nhlbihin.net/atpiii/ calculator.asp?usertype=prof.)
22. National Heart, Lung, and Blood Institute. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (Accessed April 1, 2010, at http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.)
23. Casey PR, Dunn G, Kelly BD, et al. Factors associated with suicidal ideation in the general population: five-centre analysis from the ODIN study. Br J Psychiatry 2006;189:410-5. (Pubitemid 44683172)
24. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9. (Pubitemid 47243713)
25. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
26. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
27. Dewey RB II, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007;64:377-80.
28. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29:80-6.
29. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. [Erratum, JAMA 2006;295:1252.]
30. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003;27:1437-46.
31. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333-41.